• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Zymergen Inc.

    2/14/22 3:22:50 PM ET
    $ZY
    Industrial Specialties
    Industrials
    Get the next $ZY alert in real time by email
    SC 13G 1 tm226145d1_sc13g.htm SCHEDULE 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d)

    AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

    (Amendment No. ___________) *

     

    Zymergen Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001

    (Title of Class of Securities)

     

    98985X100

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨           Rule 13d-1(b)

     

    ¨           Rule 13d-1(c)

     

    x          Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

    Exhibit Index Contained on Page 13

     

     

     

     

    CUSIP NO. 98985X100 13G Page 2 of 14

     

    1 NAME OF REPORTING PERSON              Data Collective II, L.P. (“DCVC II”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)           ¨           (b)           x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH
    5 SOLE VOTING POWER
    2,448,901 shares, except that Data Collective II GP, LLC (“DCVC II GP”), the general partner of DCVC II, may be deemed to have sole voting power with respect to such shares, and Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of DCVC II GP, may be deemed to have shared voting power with respect to such shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    2,448,901 shares, except that DCVC II GP, the general partner of DCVC II, may be deemed to have sole voting power with respect to such shares, and Bogue and Ocko, the managing members of DCVC II GP, may be deemed to have shared dispositive power with respect to such shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON                    2,448,901
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES*                     ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.4%

    12

    TYPE OF REPORTING PERSON*

    PN

           

     

    CUSIP NO. 98985X100 13G Page 3 of 14

     

    1 NAME OF REPORTING PERSON              Data Collective II GP, LLC (“DCVC II GP”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)           ¨           (b)           x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH
    5 SOLE VOTING POWER
    2,448,901 shares, all of which are held by Data Collective II, L.P. (“DCVC II”), for whom DCVC II GP serves as general partner, except that Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of DCVC II GP, may be deemed to have shared voting power with respect to such shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    2,448,901 shares, all of which are held by DCVC II, for whom DCVC II GP serves as general partner, except that Bogue and Ocko, the managing members of DCVC II GP, may be deemed to have shared dispositive power with respect to such shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON                    2,448,901
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                     ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.4%

    12

    TYPE OF REPORTING PERSON*

    OO

           

     

    CUSIP NO. 98985X100 13G Page 4 of 14

     

    1 NAME OF REPORTING PERSON              DCVC Opportunity Fund, L.P. (“DCVC OF”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)           ¨           (b)           x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH
    5 SOLE VOTING POWER
    4,917,734 shares, except that DCVC Opportunity Fund GP, LLC (“DCVC OF GP”), the general partner of DCVC OF, may be deemed to have sole voting power with respect to such shares, and Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of DCVC OF GP, may be deemed to have shared voting power with respect to such shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    4,917,734 shares, except that DCVC OF GP, the general partner of DCVC OF, may be deemed to have sole voting power with respect to such shares, and Bogue and Ocko, the managing members of DCVC OF GP, may be deemed to have shared dispositive power with respect to such shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON                    4,917,734
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES*                     ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.8%

    12

    TYPE OF REPORTING PERSON*

    PN

           

     

    CUSIP NO. 98985X100 13G Page 5 of 14

     

    1 NAME OF REPORTING PERSON              DCVC Opportunity Fund GP, LLC (“DCVC OF GP”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)           ¨           (b)           x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH
    5 SOLE VOTING POWER
    4,917,734 shares, all of which are held by DCVC Opportunity Fund, L.P. (“DCVC OF”), for whom DCVC OF GP serves as general partner, except that Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of DCVC OF GP, may be deemed to have shared voting power with respect to such shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    4,917,734 shares, all of which are held by DCVC OF, for whom DCVC OF GP serves as general partner, except that Bogue and Ocko, the managing members of DCVC OF GP, may be deemed to have shared dispositive power with respect to such shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON                    4,917,734
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                     ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.8%

    12

    TYPE OF REPORTING PERSON*

    OO

           

     

    CUSIP NO. 98985X100 13G Page 6 of 14

     

    1 NAME OF REPORTING PERSON              Zachary Bogue (“Bogue”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)           ¨           (b)           x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S. Citizen

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH
    5

    SOLE VOTING POWER
    0 shares

    6 SHARED VOTING POWER
    7,366,635 shares, of which (a) 2,448,901 are held by Data Collective II, L.P. (“DCVC II”) and (b) 4,917,734 are held by DCVC Opportunity Fund, L.P. (“DCVC OF”).  Bogue is (i) a managing member of Data Collective II GP, LLC (“DCVC II GP”), the general partner of DCVC II, and (ii) a managing member of DCVC Opportunity Fund GP, LLC (“DCVC OF GP”), the general partner of DCVC OF, and may be deemed to have shared voting power with respect to such shares.  
    7 SOLE DISPOSITIVE POWER
    0 shares
    8 SHARED DISPOSITIVE POWER
    7,366,635 shares, of which (a) 2,448,901 are held by DCVC II and (b) 4,917,734 are held by DCVC OF.  Bogue is (i) a managing member of DCVC II GP, the general partner of DCVC II, and (ii) a managing member of DCVC OF GP, the general partner of DCVC OF, and may be deemed to have shared dispositive power with respect to such shares.  
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON                    7,366,635
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                     ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.2%

    12

    TYPE OF REPORTING PERSON*

    IN

           

     

    CUSIP NO. 98985X100 13G Page 7 of 14

     

    1 NAME OF REPORTING PERSON              Matthew Ocko (“Ocko”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)           ¨           (b)           x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S. Citizen

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH
    5 SOLE VOTING POWER
    0 shares
    6 SHARED VOTING POWER
    7,366,635 shares, of which (a) 2,448,901 are held by Data Collective II, L.P. (“DCVC II”) and (b) 4,917,734 are held by DCVC Opportunity Fund, L.P. (“DCVC OF”).  Ocko is (i) a managing member of Data Collective II GP, LLC (“DCVC II GP”), the general partner of DCVC II, and (ii) a managing member of DCVC Opportunity Fund GP, LLC (“DCVC OF GP”), the general partner of DCVC OF, and may be deemed to have shared voting power with respect to such shares.  
    7 SOLE DISPOSITIVE POWER
    0 shares
    8 SHARED DISPOSITIVE POWER
    7,366,635 shares, of which (a) 2,448,901 are held by DCVC II and (b) 4,917,734 are held by DCVC OF.  Ocko is (i) a managing member of DCVC II GP, the general partner of DCVC II, and (ii) a managing member of DCVC OF GP, the general partner of DCVC OF, and may be deemed to have shared dispositive power with respect to such shares.  
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON                    7,366,635
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                     ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.2%

    12

    TYPE OF REPORTING PERSON*

    IN

           

     

     

    CUSIP NO. 98985X100 13G Page 8 of 14

     

     

    ITEM 1(A).NAME OF ISSUER

    Zymergen Inc.

     

    ITEM 1(B).

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

     

    5980 Horton Street, Suite 105

    Emeryville, California 94608

     

    ITEM 2(A).

    NAME OF PERSONS FILING

     

    This Statement is filed by Data Collective II, L.P., a Delaware limited partnership (“DCVC II”), Data Collective II GP, LLC, a Delaware limited liability company (“DCVC II GP”), DCVC Opportunity Fund, L.P., a Delaware limited partnership (“DCVC OF”), DCVC Opportunity Fund GP, LLC, a Delaware limited liability company (“DCVC OF GP”), Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”). The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

     

    DCVC II GP is the general partner of DCVC II, and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC II. Bogue and Ocko are managing members of DCVC II GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC II.

     

    DCVC OF GP is the general partner of DCVC OF, and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC OF. Bogue and Ocko are managing members of DCVC OF GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC OF.

     

    ITEM 2(B).ADDRESS OF PRINCIPAL OFFICE

     

    The address for each of the Reporting Persons is:

     

    270 University Avenue
    Palo Alto, CA 94301

     

    ITEM 2(C).

    CITIZENSHIP

     

     

    DCVC II and DCVC OF are Delaware limited partnerships. DCVC II GP and DCVC OF GP are Delaware limited liability companies. Bogue and Ocko are United States citizens.

     

    ITEM 2(D) AND (E).TITLE OF CLASS OF SECURITIES AND CUSIP NUMBER

     

    Common Stock, par value $0.001
    CUSIP # 98985X100

     

    ITEM 3.Not Applicable.

     

     

     

     

    CUSIP NO. 98985X100 13G Page 9 of 14

     

    ITEM 4.

    OWNERSHIP

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

     

    (b)Percent of Class:

    See Row 11 of cover page for each Reporting Person.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Row 6 of cover page for each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Row 7 of cover page for each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    Not applicable.

     

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

    Under certain circumstances set forth in the limited partnership agreements of DCVC II and DCVC OF, and the limited liability company agreements of DCVC II GP and DCVC OF GP, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

    Not applicable.

     

     

     

     

    CUSIP NO. 98985X100 13G Page 10 of 14

     

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

    Not applicable.

     

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP

    Not applicable.

     

    ITEM 10.CERTIFICATION

    Not applicable.

     

     

     

     

    CUSIP NO. 98985X100 13G Page 11 of 14

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2022

     

        Data Collective II, L.P.
       
        By:  Data Collective II GP, LLC, its General Partner
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member
       
        Data Collective II GP, LLC
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue                                                 
      Title: Managing Member
       
        DCVC Opportunity Fund, L.P.
       
        By:  DCVC Opportunity Fund GP, LLC, its General Partner
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member
       
        DCVC Opportunity Fund GP, LLC
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member
       
        Matthew Ocko
       
      By: /s/ Matthew Ocko
      Name: Matthew Ocko
       
        Zachary Bogue
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

     

     

     

    CUSIP NO. 98985X100 13G Page 12 of 14

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for

    other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

     

     

     

    CUSIP NO. 98985X100 13G Page 13 of 14

     

    EXHIBIT INDEX

     

      Found on Sequentially
    Exhibit Numbered Page
    Exhibit A:  Agreement of Joint Filing 14

     

     

     

     

    CUSIP NO. 98985X100 13G Page 14 of 14

     

    exhibit A

     

    Agreement of Joint Filing

     

    The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of Zymergen Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

     

    Date: February 14, 2022

     

        Data Collective II, L.P.
       
        By:  Data Collective II GP, LLC, its General Partner
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member                                             
       
        Data Collective II GP, LLC
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member
       
        DCVC Opportunity Fund, L.P.
       
        By:  DCVC Opportunity Fund GP, LLC, its General Partner
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member
       
        DCVC Opportunity Fund GP, LLC
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member
       
        Matthew Ocko
       
      By: /s/ Matthew Ocko
      Name: Matthew Ocko
       
        Zachary Bogue
       
      By: /s/ Zachary Bogue
      Name: Zachary Bogue

     

     

     

    Get the next $ZY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZY

    DatePrice TargetRatingAnalyst
    3/2/2022Market Perform
    Cowen
    1/12/2022$6.50Reduce → Hold
    HSBC Securities
    10/15/2021Market Perform
    Cowen
    9/27/2021$12.00Neutral → Underweight
    JP Morgan
    8/31/2021$56.00 → $13.00Buy → Neutral
    UBS
    8/4/2021$43.00 → $7.00Buy → Underperform
    BofA Securities
    8/4/2021Outperform → Market Perform
    Cowen & Co.
    8/4/2021$55.00 → $12.00Buy → Neutral
    Goldman Sachs
    More analyst ratings

    $ZY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Bioworks Completes Acquisition of Zymergen

    BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, and Zymergen (NASDAQ:ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome t

    10/19/22 9:08:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

    EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability of operations for its existing platform. Octant has now more than doubled its initial investment through the purchase of an additional six RAC units, vastly increasing the system's throughput, capabilities, and ability to run complex workflows. "We've been extremely pleased with the performance of our current RAC System and are l

    7/14/22 4:56:39 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    SEC Filings

    View All

    SEC Form 15-12G filed by Zymergen Inc.

    15-12G - Zymergen Inc. (0001645842) (Filer)

    10/31/22 4:47:58 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form EFFECT filed by Zymergen Inc.

    EFFECT - Zymergen Inc. (0001645842) (Filer)

    10/26/22 12:15:12 AM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form POS AM filed by Zymergen Inc.

    POS AM - Zymergen Inc. (0001645842) (Filer)

    10/19/22 12:36:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Svf Excalibur (Cayman) Ltd disposed of 26,614,219 shares

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/21/22 4:30:20 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Flatley Jay T returned 144,789 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:17:59 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Chu Steven returned 50,000 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:15:58 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    3/2/22 8:44:04 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Zymergen from Reduce to Hold and set a new price target of $6.50

    1/12/22 7:08:41 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    10/15/21 7:34:23 AM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Financials

    Live finance-specific insights

    View All

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Reports Preliminary First Quarter 2022 Financial Results

    EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the first quarter ended March 31, 2022. "Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process," said Zymergen's interim CEO, Jay Flatley. "We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation." Preliminary First Quarter 2022 Financial ResultsTotal r

    5/12/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022

    EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. Investor Contactinvest

    4/13/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)

    SC 13G/A - Zymergen Inc. (0001645842) (Subject)

    10/21/22 4:31:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 3:22:50 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 9:36:54 AM ET
    $ZY
    Industrial Specialties
    Industrials